KNSA — Kiniksa Pharmaceuticals International Share Price
Last trade - 00:00- $1.56bn
- $1.31bn
- $423.24m
- 66
- 22
- 55
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 31.76 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.55 | ||
| Price to Tang. Book | 3.69 | ||
| Price to Free Cashflow | 61.33 | ||
| Price to Sales | 3.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.5% | ||
| Return on Equity | -9.85% | ||
| Operating Margin | -10.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 38.54 | 220.18 | 270.26 | 423.24 | 578.45 | 698.99 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -92.48 | n/a | n/a | +94.02 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.
Directors
- Sanjiv Patel CHM (51)
- Mark Ragosa CFO (47)
- Eben Tessari COO (40)
- John Paolini SVP (56)
- Madelyn Zeylikman VPR
- Ross Moat VPR (40)
- Felix Baker LED (52)
- Stephen Biggar IND (50)
- G. Bradley Cole IND (65)
- Richard Levy IND (63)
- Thomas Malley IND (52)
- Tracey McCain IND (53)
- Kimberly Popovits IND (62)
- Barry Quart IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 9th, 2024
- Public Since
- May 24th, 2018
- No. of Shareholders
- 7
- No. of Employees
- 315
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 72,949,544
- Address
- 23 Old Bond Street, Floor 3, LONDON, WIS 4PZ
- Web
- https://www.kiniksa.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for KNSA
Similar to KNSA
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 21:35 UTC, shares in Kiniksa Pharmaceuticals International are trading at $21.37. This share price information is delayed by 15 minutes.
Shares in Kiniksa Pharmaceuticals International last closed at $21.37 and the price had moved by +21.32% over the past 365 days. In terms of relative price strength the Kiniksa Pharmaceuticals International share price has outperformed the S&P500 Index by +11.99% over the past year.
The overall consensus recommendation for Kiniksa Pharmaceuticals International is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreKiniksa Pharmaceuticals International does not currently pay a dividend.
Kiniksa Pharmaceuticals International does not currently pay a dividend.
Kiniksa Pharmaceuticals International does not currently pay a dividend.
To buy shares in Kiniksa Pharmaceuticals International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $21.37, shares in Kiniksa Pharmaceuticals International had a market capitalisation of $1.56bn.
Here are the trading details for Kiniksa Pharmaceuticals International:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: KNSA
Based on an overall assessment of its quality, value and momentum Kiniksa Pharmaceuticals International is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Kiniksa Pharmaceuticals International is $35.57. That is 66.49% above the last closing price of $21.37.
Analysts covering Kiniksa Pharmaceuticals International currently have a consensus Earnings Per Share (EPS) forecast of $0.52 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kiniksa Pharmaceuticals International. Over the past six months, its share price has underperformed the S&P500 Index by -17.94%.
As of the last closing price of $21.37, shares in Kiniksa Pharmaceuticals International were trading -5.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kiniksa Pharmaceuticals International PE ratio based on its reported earnings over the past 12 months is 31.76. The shares last closed at $21.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kiniksa Pharmaceuticals International's management team is headed by:
- Sanjiv Patel - CHM
- Mark Ragosa - CFO
- Eben Tessari - COO
- John Paolini - SVP
- Madelyn Zeylikman - VPR
- Ross Moat - VPR
- Felix Baker - LED
- Stephen Biggar - IND
- G. Bradley Cole - IND
- Richard Levy - IND
- Thomas Malley - IND
- Tracey McCain - IND
- Kimberly Popovits - IND
- Barry Quart - IND